blog

It is a great pleasure for us to introduce our Head of Regulatory and Clinical Affairs, who joined Glycanostics in February this year. Zuzana Batova

It was my great pleasure to present Glycanostics® and our early-stage cancer diagnostic test Giasay® at the EIC & EuroQuity – Bpifrance Healthcare Investor Day on 23 October in

„Glycanostics® is going to be one of 25 most innovative companies that will compete at a pitch competition at the HealthTech Innovation Days (HTID®) in

Meet our CEO Eva Kovacova FCCA at the European Angel Investment Summit in Brussels on 10-11 October! Join me at the premier annual conference where angels, entrepreneurs,

First Patent Certificate for EP Patent No. 3 775 909 for us! Availabe here.

The Glycanostics cancer screening technology detects glycan changes (complex carbohydrates) attached to a protein in the blood. It is highly scalable  due to the following

8th & 9th March, 2023, Brussels Our CEO Eva Kováčová is one of the organisers of the first summit by the EU Female Founders in

Glycanostics took another important step to improve its quality management system and has been granted with ISO 13485.

Glycanostics was selected as one of eight most innovative companies to participate in the MEDICAL FORGE Accelerator program 2023, which will facilitate and accelerate our

Glycanostics was invited to attend the EIC Summit that took place on 7th and 8th December in Brussels. We have spent two days learning about

Glycanostics was honoured to be invited for the EIC Corporate Day with Medtronic and Fresenius Kabi in November 2022. We presented our innovative approach to

Glycanostics, Ltd. hosted an important visit – 17 ambassadors from different countries from Asia, Europe, South America and USA. We introduced them our company, explained the